Inhibitors of acetyl-CoA carboxylase for treatment of neuronal hypometabolism

Details for Australian Patent Application No. 2008251742 (hide)

Owner Neuera Pharmaceuticals, Inc.

Inventors Henderson, Samuel T.

Agent Davies Collison Cave

Pub. Number AU-A-2008251742

PCT Pub. Number WO2008/140828

Priority 60/917,886 14.05.07 US

Filing date 14 May 2008

Wipo publication date 20 November 2008

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 31/35 (2006.01) - having six-membered rings with one oxygen as the only ring hetero atom

C07D 407/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C12N 9/99 (2006.01) Enzymes, e.g. ligases (6.) - Enzyme inactivation by chemical treatment

Event Publications

10 December 2009 PCT application entered the National Phase

  PCT publication WO2008/140828 Priority application(s): WO2008/140828

20 January 2011 Alteration of Name

  The name of the applicant has been altered to Accera, Inc.

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  Application withdrawn under section 141(1). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008251748-Novel antimicrobial peptides

2008251723-Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases